(Bloomberg) – U.S. medical technology company Fluidigm Corp. is considering a sale, people familiar with the matter said.
The company works with an advisor to pique the interest of potential buyers, according to people, who have asked not to be identified because the information is private. Fluidigm could attract other health care companies as well as private equity firms, the people said.
The deliberations are ongoing and there is no certainty that they will lead to a transaction, the people said. A representative for Fluidigm declined to comment.
Fluidigm shares have risen 5.8% this year, giving the South San Francisco-based company a market value of around $ 476 million. Shares rose more than 10% after regular trading closed on Tuesday.
Fluidigm’s lab equipment helps researchers analyze cells and genomes to target diseases like cancer and immune dysfunction. The company released a Covid-19 saliva test that received emergency use clearance last August from the United States Food and Drug Administration.
Mergers and acquisitions involving healthcare companies nearly tripled this year to $ 350.7 billion, according to data compiled by Bloomberg. Diagnostic and medical equipment companies have been in high demand, with Thermo Fisher Scientific Inc. trying unsuccessfully last year to acquire European rival Qiagen NV.
(Updates with stock gains Tuesday in the fourth paragraph)
© 2021 Bloomberg LP